zealthy glp 1 getZealthy c2a9e641-group-238-3.svg
Description
The approval of orforglipron signals both a shift toward more accessible obesity treatments and a test case for the FDAs new accelerated review pathway
Recuperato da: Herman RJ, Hayes MR, Audrain-McGovern J, Ashare RL, Schmidt HD
May 30, 2025
A January 2024 study by Epic Research showed that more than half of people taking semaglutide or liraglutide (Victoza 2-Pak) who lost at least five pounds maintained their weight loss or lost more for a full year after discontinuing the medication
Still today, individuals with diabetes have an approximately two-fold increased risk of all-cause mortality than those without diabetes [3]
The out-of-pocket price of a months supply is $499
